Evaluation of the clinical efficacy of regorafenib (Belvango) in the treatment of patients with colorectal cancer

Regorafenib is an oral multi-target tyrosine kinase inhibitor that mainly acts on VEGFR, PDGFR, FGFR , KIT, RET and other signaling pathways can exert anti-tumor effects by inhibiting tumor angiogenesis, inhibiting cancer cell proliferation and blocking key signals in the tumor microenvironment. In the treatment of colorectal cancer (especially advanced or metastatic colorectal cancer), regorafenib is usually used in patients whose disease has progressed after previous standard chemotherapy or targeted therapy. Since treatment options are limited for this group of patients, the application of regorafenib provides them with new treatment hope.

In clinical studies, the efficacy of regorafenib has been fully confirmed. The most representative CORRECT study is a global multi-center, randomized, double-blind, placebo-controlled Phase III clinical trial. The results of the study showed that the median overall survival (OS) of patients in the regorafenib group was 6.4 months, while that in the placebo group was 5.0 months, the hazard ratio (HR) was 0.77, indicating that regorafenib can significantly prolong patient survival time. In addition, in terms of progression-free survival (PFS), the median PFS of the regorafenib group was 1.9 months, which was significantly better than the median PFS of 1.7 months in the placebo group. Although the gap is not particularly large, there are not many drug options that can bring survival benefits after standard treatment fails, so the clinical value of regorafenib is very prominent.

In the Asian population, the CONCUR study further verified the efficacy of regorafenib in patients with colorectal cancer. The patients included in the study were mainly from Asia, and some of them had received relatively limited previous treatment options. The results showed that the median OS in the regorafenib group was 8.8 months, while that in the placebo group was 6.3 months, with a hazard ratio of 0.55., suggesting that its benefits are more significant in Asian populations. This result not only shows that regorafenib is effective in different ethnic groups, but also indicates that early use of regorafenib may lead to better clinical effects. Based on these research results, regorafenib has become one of the standard treatment options recommended by guidelines for patients with advanced colorectal cancer who have failed multiple lines of therapy.

In actual clinical application, the efficacy of regorafenib is relatively complex. Some patients can achieve longer disease control periods, even more than a year, while other patients may progress within a short period of time. Studies have shown that tumor molecular characteristics, patients' systemic conditions, and medication compliance may affect efficacy. In order to improve the efficacy and tolerability, individualized dosing strategies are often used in clinical practice, such as using a low initial dose and gradually increasing the dose to reduce initial adverse reactions and improve the patient's tolerance while ensuring the efficacy. Some studies have also explored the possibility of combining regorafenib with immunotherapy, chemotherapy or other targeted drugs. Preliminary results show that combination therapy may further improve the efficacy, but more clinical evidence is still needed to support it.

To sum up, the clinical effect of regorafenib in the treatment of colorectal cancer patients has been confirmed by multiple international and regional studies, and it can prolong the survival of patients and bring about a certain disease control rate when standard treatments fail. Although the survival benefit it brings is relatively limited, and it may be accompanied by adverse reactions such as hand-foot syndrome, fatigue, hypertension, abnormal liver function, etc., through reasonable dose adjustment and symptomatic treatment, the vast majority of patients can still continue to receive treatment. In the future, with the development of precision medicine and the in-depth exploration of combination treatment strategies, the application prospects of regorafenib in colorectal cancer are expected to be further expanded and benefit more patients.

Reference materials:https://www.drugs.com/